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Abstract
Purpose
The objective of this study was to characterize the demographic and clinical profile of RRMS
patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clini-
cal practice.
Methods
This observational, retrospective, multicentre, nationwide study was performed at 56 Span-
ish hospitals and involved 804 RRMS patients who received oral fingolimod (0.5 mg) since
November 2011, with a minimum follow-up of 12 months.
Results
The mean annualized relapse rate (ARR) in the year before fingolimod was 1.08 and the
median EDSS was 3; patients were exposed to fingolimod for 2.2 years as average; regard-
ing magnetic resonance imaging (MRI) activity, more than half of the patients had >20
lesions at baseline. Patients were previously treated with first-line injectable DMTs (60.3%),
or natalizumab (31.3%), and 8.3%were naïve patients. Overall, the ARR significantly
decreased to 0.28, 0.22 and 0.17 (74.1%, 79.7% and 83.5% of relative reduction, respec-
tively) after 12, 24 and 36 months of treatment, P<0.001. The ARR of patients who switched
from natalizumab to fingolimod was stable over the study. Most of the patients (88.7%) were
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free from confirmed disability and MRI activity (67.3%) after 24 months. The persistence
after 12 months on fingolimod was 93.9%.
Conclusions
The subgroups of patients analysed showed differential baseline demographic and clinical
characteristics. The analysis of patients who received fingolimod in routine clinical practice
confirmed adequate efficacy and safety, even for long-term treatment. The present data
also confirmed the positive benefit/risk balance with fingolimod in real-world clinical practice
setting.
Introduction
Multiple sclerosis (MS) is the most common chronic, immune-mediated, and neurodegenera-
tive disease in young adults.[1,2] Fingolimod (Gilenya1, Novartis Pharma AG), a sphingosine
1-phosphate receptor modulator, was the first oral drug approved in Spain for treating remit-
ting-relapsing multiple sclerosis (RRMS) patients.[3] Fingolimod acts as a functional antago-
nist of the sphingosine-1-phosphate type 1 receptor, inducing receptor internalization and
rendering T and B cells insensitive to the egress signals from secondary lymphoid tissues. The
resulting lymphocyte redistribution reduces recirculation of auto-aggressive cells to the central
nervous system.[4] Due to the lipophilic nature of the drug, fingolimod crosses the blood–
brain barrier, and is phosphorylated within the central nervous system.[5] The efficacy of fin-
golimod was proved in 3 phase III randomized clinical trials: FREEDOMS, FREEDOMS II,
and TRANSFORMS,[6–8] showing higher efficacy in reducing annual relapse rate (ARR), dis-
ability worsening, and magnetic resonance imaging (MRI) activity compared to placebo and
over interferon (IFN) beta 1-a. Additionally, fingolimod reduced brain volume loss (BVL),
suggesting its potential dual action over the disease inflammation and neurodegeneration.[9]
Adherence to disease-modifying therapies (DMTs) have been associated to decreased risk of
relapses and to the improved health-related quality-of-life.[10] It has been reported that
patients on fingolimod had higher treatment compliance than patients on injectable DMT
(iDMT).[11] To date, there are limited multicentre studies conducted in large cohorts of
patients within the real-world setting. The objective of the present study was to characterize
the demographic and clinical profile of RRMS patients receiving fingolimod, and to evaluate
the drug effectiveness and safety after at least 12 months of follow-up in the Spanish clinical
practice setting.
Materials andmethods
Study design
This observational, retrospective, multicentre, nationwide study involved patients with RRMS
who received treatment with oral fingolimod (Gilenya1 0.5 mg) between November 2011 and
December 2015. The study was performed in 56 hospitals, in Spain.
Inclusion criteria were: women and men older than 18; with diagnosis of RRMS according
to McDonald criteria 2010;[12] having initiated treatment with fingolimod, with available fol-
low-up data from a period of, at least, 12 months, and with sufficient data in the clinical his-
tory. Patients were included according to the following criteria: 1) patients with high disease
activity despite a complete course of treatment with, at least, one DMT, or “non-responder”
PLOS ONE Real-world experience with fingolimod in RRMS patients
PLOSONE | https://doi.org/10.1371/journal.pone.0230846 April 2, 2020 2 / 13
authors are articulated in the ‘author contributions’
section.
Competing interests: Authors have read the
journal’s policy and the authors of this manuscript
have the following competing interests: - Francisco
Barrero has received consulting or speaking fees
from Almirall, Biogen, Genzyme, Merck Serono,
Novartis, Roche, Sanofi and Teva. Francisco
Barrero discloses no conflict of interest in the
elaboration of this paper. - Javier Mallada-Frechin
has received consulting or speaking fees from
Almirall, Biogen, Genzyme, Merck Serono,
Novartis, Roche, Sanofi and Teva. Javier Mallada-
Frechin discloses no conflict of interest in the
elaboration of this paper. - Maria Luisa Martı´nez-
Gine´s discloses no conflict of interest. - Marı´a
Eugenia Marzo discloses no conflict of interest. -
Virginia Meca-Lallana has received consulting or
speaking fees from Almirall, Biogen, Genzyme,
Merck Serono, Novartis, Roche, Terumo, Sanofi
and Teva. Virginia Meca-Lallana discloses no
conflict of interest in the elaboration of this paper.
Response to Reviewers - Guillermo Izquierdo has
received consulting or speaking fees from Actelion,
Almirall, Bayer, Biogen-Idec, Celgene, Merck
Serono, Novartis, Roche, Sanofi and Teva; and
research support from Almirall, Bayer, Biogen Idec,
Merck Serono, Novartis, Sanofi and Teva.
Guillermo Izquierdo discloses no conflict of interest
in the elaboration of this paper. - Jose´ Ramo´n Ara
has received consulting honoraria from Genzyme,
Novartis and Sanofi; and honoraria for lecturing or
travel expenses for attending meetings from
Biogen Idec, Genzyme, Novartis and Sanofi-
Aventis. Jose´ Ramo´n Ara discloses no conflict of
interest in the elaboration of this paper. - Celia
Oreja-Guevara has received consulting or speaking
fees from Actelion, Biogen, Merck Serono,
Genzyme, Novartis, Roche, Sanofi, Teva, and
Novartis. Celia Oreja-Guevara discloses no conflict
of interest in the elaboration of this paper. - Jose´
Meca-Lallana has received consulting or speaking
fees from Biogen, Celgene, Genzyme, Merck
Serono, Novartis, Roche, and Teva. Jose´ Meca-
Lallana discloses no conflict of interest in the
elaboration of this paper. - Lucı´a Forero has
received consulting or speaking fees from Biogen,
Merck Serono, Novartis, Roche and Sanofi. Lucı´a
Forero discloses no conflict of interest in the
elaboration of this paper. - ISV and MJM are
employed by Novartis Farmace´utica, S.A. There are
no patents, products in development or marketed
products to declare. The ISV and MJM’s
commercial affiliation do not alter our adherence to
PLOS ONE policies on sharing data and materials.
patients defined as patients who experienced� 1 relapse one year before fingolimod initiation
(while receiving a previous DMT), and that had� 9 T2 lesions in the baseline brain MRI, or
�1 gadolinium-enhancing MRI lesion; or as patients with an equal or greater ARR compared
with the previous year; 2) naïve patients with rapid evolving MS (defined by�2 relapses in a
year, and�1 gadolinium-enhancing T1 lesions on the baseline brain MRI- or a significant
increase in the T2 lesion load, compared with a previous recent MRI); and 3) patients who ini-
tiated fingolimod after withdrawal of natalizumab (NTZ). Exclusion criteria were: patients
who had received fingolimod, as part of a clinical trial, before the inclusion in the study; or
with clinical manifestation of MS other than RRMS. Treatment with fingolimod could be tem-
porarily or permanently discontinued during the 12 months of follow-up.
Recruitment started in November 2014 and ended in December 2015. Procedures were in
concordance with the guidelines established in the Declaration of Helsinki, and performed fol-
lowing Good Clinical Practice guidelines.
The Clinical Research Ethics Committee of the Hospital Clinic of Barcelona was the refer-
ence ethics committee which approved the study in September 2014 (EPA Reg. HCB/2014/
0849). In the other study sites, the study was approved by their respective ethics committees or
by the hospital management, depending on the internal procedures of each site. Given the ret-
rospective nature of this study design, informed consent was not obtained and not requested
by ethics committees.
Groups and variables
Patients were stratified in 3 subgroups according to previous treatments: those previously
treated with iDMT(s) as first-line treatment(s) (including subcutaneous or intramuscular IFN
beta-1a, subcutaneous IFN beta-1b and subcutaneous glatiramer acetate (GA); named Post-
iDMTs), patients previously treated with NTZ (Post-NTZ), or patients who did not receive
any DMT in the previous year (Naïve). Naïve patients included patients who did not receive
any previous treatment (aggressive RRMS) and those who received a previous DMT (at least
24 months prior to fingolimod initiation).
The level of disability was determined by using the Expanded Disability Status Scale
(EDSS).[13] Time to 3-month CD (confirmed disability) was defined as an increase of�1
point in the EDSS score when baseline EDSS�1, or an increase of�1.5 points, when baseline
EDSS = 0, confirmed after 3 months.
Sustained improvement was defined as the reduction in�1 point in the EDSS score, and
maintained for at least 3 months. Adverse events (AEs) were collected according to fingolimod
risk management plan.
Sample size and statistical analysis
Sample size calculation was performed with the resource “Java applets for power and sample
size”.[14] A sample size of 800–900 patients provided sufficient statistical power to measure
the treatment effectiveness with an error equal to 0.02 (for the 95% CI) and detect an AE
occurring with a frequency� 0.3% (with a ±0.27 error for a 95% CI).
The 3-month CD and time to relapses were analysed using the Kaplan-Meier methodology;
the differences between groups were compared using the log-rank test. Demographic and clin-
ical characteristics of patients were compared among groups by the non-parametric Kruskal-
Wallis or Mann-Whitney-Wilcoxon tests, when appropriate.
The baseline influence of sex, age, number of T2 and T1 gadolinium-enhancing (Gd+)
lesions, and EDSS on the ARR reduction was evaluated using the analysis of covariance
(ANCOVA). The ANCOVA model included the ARR in previous year as covariable, and the
PLOS ONE Real-world experience with fingolimod in RRMS patients
PLOSONE | https://doi.org/10.1371/journal.pone.0230846 April 2, 2020 3 / 13
following factors: time, previous treatment, and its interaction. Differences among groups
regarding sustained improvement, stability or disease worsening were analysed using the Fish-
er’s Exact test. Statistical significance was established with P< 0.05. All statistical procedures
were performed by using SAS v9.4 software (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics of patients
A total of 872 patients were initially recruited and 804 were considered evaluable. Sixty-eight
patients (7.8%) were excluded for: not having the minimum clinical information in the medi-
cal records (n = 47); or having received a previous treatment different to IFN beta, GA, or
NTZ (n = 21).
The majority of patients were female (68.5%), with a median age of 41.0 years (SD 9.1).
Patients initiated treatment with fingolimod 8.9 years (SD 6.0) after RRMS diagnosis and were
on fingolimod 2.2 years (SD 0.8) (Table 1).
The number of previous DMTs in the Post-NTZ (2.6, SD 0.9) was significantly higher than
in the Post-iDMTs patients (1.7, SD 0.9). The main reason for initiating treatment with fingoli-
mod was the lack of effectiveness of the previous treatment (58.3% of patients), followed by the
increased risk of progressive multifocal leukoencephalopathy (PML) with NTZ (28.9%). At
study initiation, the median EDSS was 3.0 (IQR, 2.0–4.0; Table 1). The mean ARR one year
before fingolimod initiation was 1.08 (SD 1.13); in the Naïve group the ARR (2.47, SD 1.82)
was significantly higher than in both the Post-iDMTs (1.28, SD 0.87) and Post-NTZ groups
(0.33, SD 0.75; P<0.001; Table 1). The mean number of gadolinium-enhancing T1 lesions was
1.2 (SD 2.4) and half of the patients (51.8%) showed > 20 T2 lesions at baseline (Table 1). The
Table 1. Baseline demographic and clinical characteristics for the total population and for patient subgroups regarding previous treatment.
Post- iDMTs(N = 485,
60.3%)
Post-NTZ(N = 252,
31.3%)
Naïve(N = 67,
8.3%)
Total
(N = 804)
P-value (inter-
groups)
Age, mean years (SD)
Range (min-max)
41.2 (9.1) 41.4 (8.8) 38.6 (9.7) 41.0 (9.1) 0.079
20–69 20–63 18–64 18–69
Sex female, n (%) 347 (71.6) 162 (64.3) 42 (62.7) 551 (68.5) 0.074
Time from RRMS diagnosis to fingolimod initiation,
mean years (SD)
8.6 (5.9) 10.4 (5.5) 4.6 (6.5) 8.9 (6.0) <0.001
Duration of treatment with fingolimod, mean years
(SD)
2.1(0.8) 2.2 (0.9) 2.1 (0.9) 2.2(0.8) N.A.
Annualized relapse rate at previous year, mean (SD) 1.28 (0.87) 0.33 (0.75) 2.47 (1.82) 1.08 (1.13) <0.001
Number of relapses at 2 previous years, mean (SD) 1.8 (1.1) 0.4 (0.9) 2.0 (1.0) 1.4 (1.2) <0.001
EDSS, mean (SD) Median (IQR) 2.9 (1.5) 3.5 (1.8) 2.7 (1.8) 3.1 (1.7) <0.001
2.5 (2.0–4.0) 3.5 (2.0–4.5) 2.5 (1.5–3.5) 3.0 (2.0–4.0)
Number of gadolinium-enhanced T1 lesions, mean
(SD)�
1.3 (2.5) 0.3 (1.2) 1.7 (2.6) 1.2 (2.4) <0.001
Patients with T2 lesions, n (%) ��
<9 lesions 24 (8.1) 4 (7.4) 7 (17.5) 35 (8.9) 0.160
9–20 lesions 113 (37.9) 28 (51.9) 13 (32.5) 154 (39.3) 0.101
>20 lesions 161 (54.0) 22 (40.7) 20 (50.0) 203 (51.8) 0.193
iDMTs, injectable disease-modifying therapies; NTZ, natalizumab; RRMS, relapsing-remitting multiple sclerosis; N.A., not available; EDSS, expanded disability status
scale; IQR, interquartile range
� Calculated over 307, 57, and 40 patients with available information from Post- iDMTs, Post-NTZ, and Naïve groups, respectively.
�� Calculated over 298, 54, and 40 patients with available information from Post- iDMTs, Post-NTZ, and Naïve groups, respectively.
https://doi.org/10.1371/journal.pone.0230846.t001
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mean number of gadolinium-enhancing T1 lesions in the Post-iDMTs (1.3, SD 2.5) and the
Naïve groups (1.7, SD 2.6) was significantly higher than the Post-NTZ group (0.3, SD 1.2;
P<0.001) (Table 1). Approximately half of the patients in the Post-NTZ group (51.9%) showed
between 9 and 20 T2 lesions at baseline, whereas most of the patients in the Post-iDMTs (54%)
and Naïve groups (50%) showed more than 20 lesions.
Evaluation of effectiveness
Relapses. The ARR significantly decreased from 1.08 (SD 1.13), one year before treatment
initiation, to 0.28 (SD 0.61; -74.1%; P<0.001), 0.22 (SD 0.64; -79.7%; P<0.001), and 0.17 (SD
0.60; -83.5%; P<0.001) after 12, 24 and 36 months of treatment with fingolimod, respectively
(Fig 1 and S1 Table). Patients with a baseline EDSS�3 showed a reduction in the ARR after 24
months significantly higher than those with a baseline EDSS>3 (-0.10 [SD = 0.05], p =
0.0212). Regarding patient subgroups, the ARR significantly decreased for Post-iDMTs and
Naïve patients after 12 (0.24, SD 0.50, -81.3%; and 0.22, SD 0.60, -91.1%; respectively;
P<0.001), 24 (0.17, SD 0.48; -86.7%; and 0.13, SD 0.40, -94.7%; P<0.001), and 36 months of
treatment (0.14, SD 0.50, -89.1%; and 0.11, SD 0.40, -95.6%; P<0.001). The ARR in the Post-
NTZ group remained stable during the 36 months of treatment (0.38, SD 0.75 after 12; 0.33,
SD 0.89 after 24; and 0.22, SD 0.70 after 36 months; p<0.05 in all cases; Fig 1). A total of 534
patients (66.4%) had no relapse during the treatment with fingolimod. The first relapse
occurred 26.6 months (SD 0.5) after fingolimod initiation in 33.6% of the patients. The median
Fig 1. Annualized relapse rate (ARR) one year before initiation and after 12, 24 and 36 months of treatment with fingolimod. 95% confidence intervals are shown
(black lines). � p-value< 0.05; iDMTs, injectable disease-modifying therapies; NTZ, natalizumab.
https://doi.org/10.1371/journal.pone.0230846.g001
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time elapsed between the treatment initiation and the first relapse in the Post-NTZ group was
significantly lower than in the Post-iDMTs and Naïve groups (P = 0.024; S1 Table).
Disability. In all the groups analysed (post-iDMTs, post-NTZ, naïve patients), the major-
ity of patients showed a sustained stability at 12 months (post-iDMTs 72.3%; post-NTZ 82.9%;
naïve 62.5%) and at 24 months (post-iDMTs 65.1%; post-NTZ 73.7%; naïve 64.7%) in
disability.
Although the percentage of patients with disability was similar between groups (11.3% of
total patients), the percentage of patients with sustained improvement after 12 months in the
Post-iDMTs (17.0%) and Naïve groups (27.5%) was numerically higher than in Post-NTZ
group (4.4%) (Fig 2).
Fig 2. Change in the Expanded Disability Status Scale (EDSS) between one year before treatment initiation and 12 and 24 months of treatment with fingolimod.
iDMTs, injectable disease-modifying therapies; NTZ, natalizumab.
https://doi.org/10.1371/journal.pone.0230846.g002
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Radiological activity. The number of T1 Gd+ lesions significantly (P<0.001) decreased
from 1.2 to 0.4 (SD 1.1) after 12 months, and to 0.1 (SD 0.3) after 24 months in the total popu-
lation and also in all the patient subgroups (post-iDMTs, post-NTZ and naïve) analysed (S1
Table). A 74.9% of patients were free from new/enlarged T2 lesions after 12 and 24 months on
fingolimod and 69.7% after 36 months (S1 Table). Data obtained after 36 months of treatment,
should be interpreted cautiously due to the reduced number of MRI data available.
Disease activity. The percentage of relapse-free patients after 12 and 24 months of treat-
ment with fingolimod was 78.2% and 69.2%, respectively. After 12 and 24 months of treat-
ment, the percentage of relapse-free patients was for Post-iDMTs 80.0% and 71.8%, for Naïve
82.1% and 74.6% and for Post-NTZ group 73.8% and 62.7% (Fig 3 and S1 Table).
The percentage of patients free from clinical activity after 12 and 24 months were 77.7%
and 68.3%, in the Post-iDMTs 77.6% and 68.6%in the Naïve group, and 69.4% and 56.8%in
the Post-NTZ group, respectively. Finally, the percentage of disease-free patients was 53.8%
and 38.0%, after 12 and 24 months of fingolimod treatment, respectively (S1 Fig and S1 Table).
Fig 3. MRI and relapse-free patients after 12 and 24 months of treatment with fingolimod. iDMTs, injectable disease-modifying therapies; NTZ, natalizumab.
https://doi.org/10.1371/journal.pone.0230846.g003
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The percentage of patients free from MRI was 69.4% after 12 months of treatment, and 53.5%
after 24 (Fig 3). The majority of the patients (88.7%) were free from CD during the follow-up
(S1 Table). The mean time to 3-month CD was 32.5 months (SD, 0.3 months) after treatment
initiation. The percentage of patients free from disease was 53.8% and 38.0%, after 12 and 24
months respectively (S1 Fig and S1 Table). After 12 and 24 months of treatment with fingoli-
mod, the majority of Post-iDMTs (99.8% and 90.1%), Naïve (98.4% and 93.1%) and Post-NTZ
patients (97.5% and 85.7%) were CD-free respectively. No information after 36 months of
treatment was provided due to the low number of patients.
Safety profile and treatment persistency. Most of the patients (98.3%) did not suffer any
AE following the first dose of fingolimod (Table 2); a 1.7% of the patients reported at least one
adverse event, such as atrioventricular block (0.9%) or bradycardia (0.4%). After fingolimod
initiation 20% of patients reported AEs, mostly infections (7%), liver enzymes increase (4.6%),
and lymphopenia < 200 cells/μl (2.5%). The persistence with fingolimod after 12 months was
93.9% and was similar among groups (90.7% in Post-iDMTs, 86.9% in Post-NTZ, and 91.0%
in Naïve). An 8.6% (n = 69) of the patients discontinued fingolimod during the first 12 months
of treatment: 5.7% (n = 46) permanently, and 3.9% (n = 31) temporarily. Main reason for tem-
porary discontinuation during the study period were: AEs (29 patients, 3.6%), patient decision
(9 patients, 1.1%), and pregnancy (4 patients, 0.5%); whereas for permanent discontinuation
were AEs (22 patients, 2.7%), and lack of effectiveness (19 patients, 2.4%).
Discussion
To date there are limited studies aimed to describe the demographic and clinical profile of
patients receiving fingolimod in clinical practice, and to evaluate its effectiveness and safety in
Table 2. Adverse events reported during the treatment with fingolimod for the total population and for patient subgroups regarding previous treatment.
Post- iDMTs(N = 485) Post-NTZ(N = 252) Naïve(N = 67) Total(N = 804)
After the first dose of fingolimod, n (%)
Patients with any adverse event � 9 (1.9) 3 (1.2) 2 (3.0) 14 (1.7)
Bradycardia �� 1 (0.2) 1 (0.4) 1 (1.5) 3 (0.4)
Atrioventricular block 6 (1.2) 1 (0.4) 0 (0.0) 7 (0.9)
Others 2 (0.4) 1 (0.4) 1 (1.5) 4 (0.5)
Asthenia / Fatigue 1 (0.2) 1 (0.4) 0 (0.0) 2 (0.2)
Nausea 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.1)
Dizziness 0 (0.0) 0 (0.0) 1 (1.5) 1 (0.1)
After subsequent doses of fingolimod, n (%)
Patients with any adverse event � 96 (19.8) 55 (21.8) 10 (14.9) 161 (20.0)
Infections 31 (6.4) 25 (9.9) 0 (0.0) 56 (7.0)
Liver enzymes increase 24 (5.0) 10 (4.0) 3 (4.5) 37 (4.6)
Lymphopenia (< 200 cells/μl) 13 (2.7) 5 (2.0) 2 (3.0) 20 (2.5)
Macular oedema 1 (0.2) 2 (0.8) 0 (0.0) 3 (0.4)
Pregnancy 1 (0.2) 1 (0.4) 0 (0.0) 2 (0.3)
Hypersensitivity 2 (0.4) 0 (0.0) 0 (0.0) 2 (0.3)
Symptomatic bradycardia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Atrioventricular block 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Others (no specified) 52 (10.7) 37 (14.7) 9 (13.4) 98 (12.2)
iDMTs, injectable disease-modifying therapies; NTZ, natalizumab.
� Adverse events occurred the same day or the following day to the first dose of fingolimod (initiation or re-initiation of the treatment).
�� Two bradycardia were symptomatic, and one was prolonged asymptomatic.
https://doi.org/10.1371/journal.pone.0230846.t002
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large cohorts of patients.[10,15–21] Moreover, methodologies of these studies are heteroge-
neous: performed in single Health Centre;[19–21] using diverse data sources (administrative
claims, registries, medical records);[10,15–25] with scarce and variable number of patients
(most of them < 250);[19–21] with different MS types (RRMS, progressive MS);[17–18] and/
or diverse follow-up periods.[16,19] The present MS NEXT represents the most extensive clin-
ical practise study nationally performed so far with fingolimod.
Overall population
According to our results, the patient candidate to initiate treatment with fingolimod was char-
acterized by a high disease activity, i.e. ARR, EDSS, disability, and high MRI activity. This
patient profile was more severe than found in clinical trials such as FREEDOMS, FREEDOMS
II, and TRANSFORMS studies.[6–8] Besides this, fingolimod has demonstrated to be effective
in real-word settings by reducing ARR and MRI lesions, and stabilising EDSS. In the first year
of treatment, fingolimod produced a marked reduction in the ARR, which remained stable for
the 3 years of follow-up, a stabilization of EDSS, and a decrease in MRI lesions (T1 Gd+ and
T2 lesions). The MRI results (from the second year on) should be cautiously interpreted due to
the low number of available samples. The limitation of long-term MRI data was not related to
the withdrawal of the treatment. Indeed, diverse studies have demonstrated higher rates of
treatment adherence and persistence with fingolimod.[11] However, in clinical practice, MRI
evaluation of stable patients may not be performed annually and T1 Gd+ lesions may not be
systematically analysed in every centre. Furthermore, not all the patients received fingolimod
for 3 years (some of them initiated the treatment later than others).
Naïve population
In our study, naïve patients initiating treatment with fingolimod were younger and with a
shorter time of disease evolution (from diagnosis) than overall population and other sub-
groups. Nevertheless, the naïve patients treated with fingolimod were the highly active, with
higher inflammatory activity, such as relapses and MRI lesions; showing that the choice is still
for later lines of treatments, although it has been suggested that earlier treatment is better.[26]
Regarding ARR reduction, naïve patients showed better outcomes than other subgroups
probably due to the higher baseline ARR in this subgroup of patients. Despite this, ARR
remained low during the treatment with fingolimod (from first to third year). Similarly, most
of naïve patients showed improvement in EDSS, or remained stable, through the study period.
Again, careful conclusions should be made with EDSS and MRI findings from second year due
to the low number of available samples. The limitation of this information may have occurred
for several reasons: not all the patients received fingolimod for 3 years (they could initiate later
the treatment); it was necessary a 3-month confirmed EDSS; and EDSS or MRI evaluation of
stable patients may not be routinely performed in clinical practice. The best outcomes
obtained in these naïve patients corroborate that early treatment with fingolimod is effective
for modifying the course of the disease in the clinical practice settings, and provides long-term
benefits for the patient.
Post-NTZ population
According to our results, post-NTZ patients had higher time of disease evolution and EDSS at
baseline than other subgroups. Moreover, at this time they had a lower ARR and MRI activity
presumably because they had already received a high-efficacy drug (most of them received 2 or
more previous treatments). The lack of effectiveness of the previous treatment and the
increased risk of progressive multifocal leukoencephalopathy were the main reasons for
PLOS ONE Real-world experience with fingolimod in RRMS patients
PLOSONE | https://doi.org/10.1371/journal.pone.0230846 April 2, 2020 9 / 13
switching to fingolimod. The washout period between NTZ withdrawal and the initiation of
fingolimod was heterogeneous (mean 4.52 months, SD 4.2) and was excluded from the analysis
of all variables, i.e. relapses during this period were not included in the calculation of baseline
ARR. Between NTZ withdrawal and the initiation of fingolimod, 54 out of 252 patients
(21.4%) had one relapse, and 21 out of 252 patients (8.3%) had at least two relapses. After treat-
ment with NTZ, fingolimod was able to stabilize ARR, EDSS, and MRI activity in these
patients, and controlled the disease, after 12, 24 and 36 months of treatment.
Post-iDMT population
Our results indicated that Post-iDMT patients had a long time of disability, with high inflam-
matory activity (relapses and MRI activity), and approximately half of them had received at
least one iDMT. Most of the Post-iDMT patients mainly switched to fingolimod due to the
lack of effectiveness of the previous treatment. Fingolimod treatment reduced the number of
relapses and MRI activity. Nevertheless, if comparing with naïve patients, fingolimod showed
a higher efficacy in younger patients with less time of disability, reinforcing the importance of
treating early and switching the treatment at the right time, and not too late. Most of the Post-
iDMT patients receiving fingolimod also experienced an improvement in EDSS, or remained
stable, during the whole study period. It is necessary to note that there are no data of patients
receiving oral DMT (such as dimethyl fumarate or teriflunomide) because these drugs were
not commercialized in Spain at the time of study initiation.
Treatment persistence and safety profile in overall population
Fingolimod was a well-tolerated drug, with a high persistence after 12 months of treatment, in
concordance with other studies.[6–8,11] In our study, AEs and lack of effectiveness were the
main reasons of permanent discontinuation. Reported AEs, such as infections, liver enzymes
increase, and lymphopenia < 200 cells/μl were consistent with the summary of product
characteristics.
Other studies with fingolimod in clinical practice
Several Spanish studies have demonstrated the efficacy of fingolimod in clinical practice, by
reducing ARR and MRI lesion, and stabilizing EDSS.[22–24] All of these studies share the
lower number of patients, compared with our present MS NEXT. Similarly, international stud-
ies (German, Italian, United Kingdom) have corroborated same beneficial results in real-
world settings.[25,27,28]
Limitations of the study
The methodology for evaluating some clinical outcomes (for instance, relapses or disability)
may be somehow subjective; affecting comparisons with other studies.[29] Nevertheless, this
limitation is intrinsically associated with studies in clinical practice. Moreover, potential differ-
ences with other international studies may derive from the fact that, in some countries, fingoli-
mod is indicated as first-line agent, whereas in Spain is so as second one, after failure of a
previous treatment. Another limitation in clinical practice is the MRI evaluation of stable
patients that may not be performed annually, so the information regarding the percentage of
patients free from disease should be cautiously interpreted. Besides limitations, MS NEXT is
the study at a national level in real-world settings with fingolimod involving the largest cohort
of patients.
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Conclusion
The subgroups of patients analysed showed differential demographic and clinical characteris-
tics at baseline. The analysis of patients who received fingolimod in routine clinical practice
confirmed an adequate profile of efficacy and safety, even for long-term treatment. These
results corroborate those found in pivotal clinical trials. The present data also confirm the posi-
tive benefit/risk balance of using fingolimod in real-world clinical practice setting.
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